# Copper Nitrate-Mediated Chemo- and Regioselective Annulation from Two Different Alkynes: A Direct Route to Isoxazoles

Yingying Li,<sup>†a</sup> Mingchun Gao<sup>†a</sup> Bingxin Liu,<sup>a</sup> Bin Xu<sup>\*abc</sup>

<sup>a</sup>School of Materials Science and Engineering, Department of Chemistry, Innovative Drug Research Center, Shanghai University, Shanghai 200444, China
 <sup>b</sup>State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China

<sup>c</sup>Shanghai Key Laboratory of Green Chemistry and Chemical Processes, Department of Chemistry, East China Normal University, Shanghai 200062, China

Tel: (+86) 21-66132830; Fax: (+86) 21-66132830; E-mail: xubin@shu.edu.cn

## **Supporting Information**

### **CONTENTS:**

1. General Information	S2
2. Synthesis and Characterization of Products  3. Synthetic Applications	S3
	·····S14
4. X-Ray Crystallographic Analysis for Compound 3ak	S16
5. Mechanistic Studies	S16
6. Copies of <sup>1</sup> H, <sup>13</sup> C and <sup>19</sup> F NMR Spectra for All Compounds	·····S19

#### 1. General Information

All reagents were obtained from commercial sources without further purification, and commercially available solvents were purified before use. All new compounds were fully characterized. All melting points were taken on a WRS-1A or a WRS-1B Digital Melting Point Apparatus without correction. Infrared spectra were obtained using an AVATAR 370 FT-IR spectrometer. <sup>1</sup>H, <sup>13</sup>C, and <sup>19</sup>F NMR spectra were recorded with a Bruker AV-500 spectrometer operating at 500 MHz and 125 MHz, respectively, with chemical shift values being reported in ppm relative to chloroform ( $\delta = 7.26$  ppm) or TMS ( $\delta = 0.00$  ppm) for <sup>1</sup>H NMR; chloroform ( $\delta = 77.16$  ppm) for <sup>13</sup>C NMR; and  $C_6F_6$  ( $\delta = -164.9$  ppm) for <sup>19</sup>F NMR. Mass spectra and high resolution mass spectra were recorded with an Agilent 5975N using an Electron impact (EI) or Electrospray ionization (ESI) techniques. Silica gel plate GF254 were used for thin layer chromatography (TLC) and silica gel 300-400 mesh were used for flash column chromatography. Yields refer to chromatographically and spectroscopically pure compounds, unless otherwise indicated. Unless commercially available alkynes, N-(3-ethynylphenyl)acetamide, 1-(4-ethynyl-phenyl)ethanone, 2-ethynyl-6-methoxynaphthalene,<sup>2</sup> 3-ethynyl-1-tosyl-1*H*-indole,<sup>2</sup> 1,4-diethynyl benzene,<sup>3</sup> propiolate, <sup>4</sup> 1-phenylprop-2-yn-1-ol, <sup>5</sup> 1-phenylprop-2-yn-1-one, <sup>5</sup> 4-methyl-*N*,*N*-di-(prop-2-yn-1-yl)benzenesulfonamide, N-allyl-4-methyl-N-(prop-2-yn-1-yl)-benzenesulfonamide,<sup>7</sup> 4-methyl-*N*-(prop-2-yn-1-yl)benzenesulfonamide,<sup>8</sup> (prop-2-vn-1vloxy)benzene, <sup>9</sup> 2-(prop-2-vn-1-vloxy)naphthalene, <sup>10</sup> and 2-(prop-2-yn-1-yl)isoindoline-1,3-dione<sup>11</sup> were all prepared according to the literature reported procedures.

### 2. Synthesis and Characterization of Products

$$O$$
 $CO_2$ Et

**Ethyl 3-benzoyl-isoxazole-5-carboxylate (3aa) (General Procedure):** <sup>12</sup> To a test tube were added **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) and PhCN (1.0 mL). The mixture was stirred at 60 °C under N<sub>2</sub>, then **1a** (50 μL, 0.45 mmol) in PhCN (0.5 mL) was added to the test tube through a syringe pump for 2 h. The reaction was kept stirring at 60 °C for another 0.5 h. Upon completion, the reaction mixture was cooled down to room temperature, diluted with EA and washed with water and brine. The aqueous phase was extracted with EA (3×10 mL) and the combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration through a thin pad of celite, the filtrate was evaporated in vacuum to give the crude product, which was purified by column chromatography on silica gel to give **3aa** as a white solid (68.8 mg, 94%). M.p. 68-69 °C; IR (KBr, cm<sup>-1</sup>): 1740, 1659, 1585, 1304, 1236, 886, 724, 678; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.29 (d, J = 8.0 Hz, 2H), 7.66 (t, J = 7.5 Hz, 1H), 7.53 (t, J = 8.0 Hz, 2H), 7.42 (s, 1H), 4.47 (q, J = 7.0 Hz, 2H), 1.43 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 184.5, 162.2, 161.1, 156.3, 135.2, 134.4, 130.7, 128.7, 110.1, 62.7, 14.1; LC-MS (ESI) m/z 246 [M<sup>+</sup>H].

$$O$$
 $CO_2Me$ 

**Methyl 3-benzoyl-isoxazole-5-carboxylate** (**3ab**): <sup>13</sup> Following the general procedure as for **3aa**, to the mixture of **2b** (27 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1a** (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ab** as a white solid (67.6 mg, 97%). M.p. 96-97 °C; IR (KBr, cm<sup>-1</sup>): 3142, 1731, 1656, 1443, 1287, 1254, 997, 890, 725, 678; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.29 (d, J = 8.0 Hz, 2H), 7.66 (t, J = 7.5 Hz, 1H), 7.53 (t, J = 7.5 Hz, 2H), 7.42 (s, 1H), 4.00 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 184.4, 162.2, 160.8, 156.7, 135.1, 134.5, 130.7, 128.7, 110.3, 53.2; LC-MS (ESI) m/z 232 [M<sup>+</sup>H].

$$O$$
 $CO_2Ph$ 

**Benzoyl 3-benzoyl-isoxazole-5-carboxylate** (**3ac**): Following the general procedure as for **3aa**, to the mixture of **2c** (43.8 mg, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1a** (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ac** as colorless oil (62.1 mg, 71%). IR (KBr, cm<sup>-1</sup>): 3134, 1756, 1658, 1584, 1483, 1308, 1234, 1190, 1075, 888, 732, 680; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  8.34 (d, J = 7.5 Hz, 2H), 7.70 (t, J = 7.5 Hz, 1H), 7.62 (s, 1H), 7.56 (t, J = 8.0 Hz, 2H), 7.47 (t, J = 8.0 Hz, 2H), 7.35 (t, J = 7.5 Hz, 1H), 7.27 (d, J = 8.0 Hz, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  184.3, 162.4, 160.4, 154.6, 149.7, 135.1, 134.6, 130.8, 129.8, 128.8, 126.9, 121.2, 111.3; LC-MS (ESI) m/z 294 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>12</sub>NO<sub>4</sub> [M<sup>+</sup>H]

294.0761, found 294.0758.

(Isoxazole-3,5-diyl)bis(phenylmethanone) (3ad): <sup>14</sup> Following the general procedure as for 3aa, to the mixture of 2d (39 mg, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1a (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3ad (61.7 mg, 74%). IR (KBr, cm<sup>-1</sup>): 3152, 1668, 1599, 1448, 1259, 893, 725, 687; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.35 (d, J = 7.5 Hz, 2H), 8.15 (d, J = 7.5 Hz, 2H), 7.73-7.67 (m, 2H), 7.61-7.54 (m, 4H), 7.49 (s, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 184.7, 180.9, 167.0, 161.9, 135.3, 135.2, 134.5, 134.4, 130.8, 130.0, 129.0, 128.8, 110.9; LC-MS (ESI) m/z 278 [M<sup>+</sup>H].

(5-Butylisoxazol-3-yl)(phenyl)methanone (3ae): <sup>12</sup> Following the general procedure as for 3aa, to the mixture of 2e (34 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1a (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3ae as pale yellow oil (42.7 mg, 62%). IR (KBr, cm<sup>-1</sup>): 2929, 2865, 1663, 1593, 1455, 1221, 1179, 891, 729, 687; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.29 (d, J = 7.5 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 6.52 (s, 1H), 2.84 (t, J = 7.5 Hz, 2H), 1.78-1.70 (m, 2H), 1.48-1.38 (m, 2H), 0.96 (t, J = 7.5 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 186.2, 174.7, 161.9, 135.9, 133.9, 130.6, 128.5, 101.6, 29.5, 26.3, 22.2, 13.7; LC-MS (ESI) m/z 230 [M<sup>+</sup>H].

(5-(Bromomethyl)-isoxazol-3-yl)(phenyl)methanone (3af): <sup>15</sup> Following the general procedure as for 3aa, to the mixture of 2f (26 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1a (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3af as a pale yellow solid (48.7 mg, 61%). M.p. 36-38 °C; IR (KBr, cm<sup>-1</sup>): 2924, 1854, 1649, 1596, 1454, 1261, 1222, 1089, 1023, 894, 803, 725, 683; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.29 (d, J = 7.5 Hz, 2H), 7.66 (t, J = 7.5 Hz, 1H), 7.53 (t, J = 8.0 Hz, 2H), 6.85 (s, 1H), 4.54 (s, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 185.2, 168.4, 162.1, 135.5, 134.2, 130.7, 128.7, 104.7, 18.0; EI-MS m/z (%): 268 (100) [M<sup>+</sup> (<sup>81</sup>Br)], 266 (94) [M<sup>+</sup> (<sup>79</sup>Br)].

(5-(Phenoxymethyl)-isoxazol-3-yl)(phenyl)methanone (3ag): Following the general procedure

as for **3aa**, to the mixture of **2g** (38  $\mu$ L, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1a** (50  $\mu$ L, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ag** as pale yellow oil (73.0 mg, 87%). IR (KBr, cm<sup>-1</sup>): 1657, 1592, 1495, 1455, 1246, 1068, 889, 835, 723, 679; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  8.31 (d, J = 7.5 Hz, 2H), 7.65 (t, J = 7.5 Hz, 1H), 7.53 (t, J = 7.5 Hz, 2H), 7.34 (t, J = 8.0 Hz, 2H), 7.04 (t, J = 7.5 Hz, 1H), 7.00 (d, J = 8.0 Hz, 2H), 6.89 (s, 1H), 5.25 (s, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  185.4, 168.9, 161.9, 157.6, 135.6, 134.1, 130.7, 129.8, 128.6, 122.1, 114.8, 104.4, 61.0; LC-MS (ESI) m/z: 280 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>17</sub>H<sub>14</sub>NO<sub>3</sub> [M<sup>+</sup>H] 280.0968, found 280.0965.

(5-(Naphthoxymethyl)-isoxazol-3-yl)(phenyl)methanone (3ah): Following the general procedure as for 3aa, to the mixture of 2h (54.7 mg, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1a (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3ah as pale yellow solid (59.0 mg, 60%). M.p. 110-111 °C; IR (KBr, cm<sup>-1</sup>): 3051, 1662, 1600, 1510, 1458, 1391, 1254, 1216, 1185, 1053, 887, 736, 682; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.32 (d, J = 7.5 Hz, 2H), 7.80 (d, J = 9.0 Hz, 2H), 7.76 (d, J = 8.0 Hz, 1H), 7.66 (t, J = 7.5 Hz, 1H), 7.53 (t, J = 7.5 Hz, 2H), 7.48 (t, J = 7.5 Hz, 1H), 7.39 (t, J = 7.5 Hz, 1H), 7.25-7.21 (m, 2H), 6.93 (s, 1H), 5.36 (s, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 185.4, 168.8, 161.9, 155.6, 135.6, 134.2, 134.1, 130.7, 130.0, 129.5, 128.6, 127.8, 127.0, 126.7, 124.3, 118.5, 107.3, 104.5, 61.1; LC-MS (ESI) m/z 330 [M<sup>+</sup>H]. HRMS (ESI) m/z calcd for C<sub>21</sub>H<sub>16</sub>NO<sub>3</sub> [M<sup>+</sup>H] 330.1125, found 330.1122.

(5-(Hydroxymethyl)-isoxazol-3-yl)(phenyl)methanone (3ai): <sup>16</sup> Following the general procedure as for 3aa, to the mixture of 2i (18 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1a (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3ai as pale yellow oil (36.1 mg, 59%). IR (KBr, cm<sup>-1</sup>): 3425, 1662, 1593, 1452, 1181, 892, 730, 687; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.25 (d, J = 8.0 Hz, 2H), 7.64 (t, J = 7.5 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 6.76 (s, 1H), 4.84 (s, 2H), 2.97 (br, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 185.9, 172.4, 161.7, 135.6, 134.2, 130.7, 128.6, 102.9, 56.3; LC-MS (ESI) m/z 204 [M<sup>+</sup>H].

*N*-((3-Benzoyl-isoxazol-5-yl)methyl)-4-methylbenzenesulfonamide (3aj): Following the general procedure as for **3aa**, to the mixture of **2j** (62.8 mg, 0.3 mmol),  $Cu(NO_3)_2 \cdot 3H_2O$  (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1a** (50  $\mu$ L, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3aj** as a

white solid (75.4 mg, 73%). M.p. 109-110 °C; IR (KBr, cm<sup>-1</sup>): 3252, 1662, 1596, 1447, 1320, 1157, 1071, 889, 727, 679; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  8.18 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 8.0 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.49 (t, J = 8.0 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H), 6.52 (s, 1H), 5.78 (t, J = 6.5 Hz, 1H), 4.38 (d, J = 6.5 Hz, 2H), 2.33 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  185.3, 168.7, 161.6, 144.1, 136.4, 135.4, 134.2, 130.6, 129.9, 128.6, 127.1, 103.8, 38.6, 21.5; LC-MS (ESI) m/z 357 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>18</sub>H<sub>17</sub>N<sub>2</sub>O<sub>4</sub>S [M<sup>+</sup>H] 357.0904, found 357.0903.

**2-((3-Benzoylisoxazol-5-yl)methyl)isoindoline-1,3-dione** (**3ak):** Following the general procedure as for **3aa**, to the mixture of **1a** (55.6 mg, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **2k** (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ak** as a white solid (74.6 mg, 75%). M.p. 156-157 °C; IR (KBr, cm<sup>-1</sup>): 3478, 1768, 1721, 1664, 1597, 1386, 1251, 1186, 947, 890, 737; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.25 (d, J = 7.5 Hz, 2H), 7.90 (m, 2H), 7.77 (m, 2H), 7.60 (t, J = 7.5 Hz, 1H), 7.49 (t, J = 7.5 Hz, 2H), 6.77 (s, 1H), 5.08 (s, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 185.3, 167.5, 167.1, 162.0, 135.5, 134.5, 134.1, 131.8, 130.7, 128.6, 123.8, 104.0, 33.1; LC-MS (DART) m/z 333 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>19</sub>H<sub>13</sub>N<sub>2</sub>O<sub>4</sub> [M<sup>+</sup>H] 333.0870, found 333.0865.

(5-(Hydroxyl(phenyl)methyl)isoxazol-3-yl)(phenyl)methanone (3al): Following the general procedure as for 3aa, to the mixture of 2l (39 mg, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1a (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3al as yellow oil (42.4 mg, 51%). IR (KBr, cm<sup>-1</sup>): 3454, 2921, 1655, 1588, 1451, 1231, 1180, 891, 729, 690; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.26 (d, J = 8.0 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.53-7.44 (m, 4H), 7.43-7.35 (m, 3H), 6.67 (s, 1H), 6.00 (s, 1H), 3.06 (br, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 185.8, 174.4, 161.6, 139.1, 135.6, 134.1, 130.7, 129.0, 128.9, 128.6, 126.6, 102.8, 69.4; LC-MS (ESI) m/z 280 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>17</sub>H<sub>14</sub>NO<sub>3</sub> [M<sup>+</sup>H] 280.0968, found 280.0966.

(5-(2-Hydroxypropan-2-yl)isoxazol-3-yl)(phenyl)methanone (3am): Following the general procedure as for 3aa, to the mixture of 2m (29 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1a (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3am as yellow oil (52.2 mg, 75%). IR (KBr, cm<sup>-1</sup>): 3441, 2983, 1661, 1590, 1454, 1235, 1180, 892, 732, 687; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  8.26 (d, J = 7.5 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 8.0 Hz,

2H), 6.68 (s, 1H), 2.84 (br, 1H), 1.67 (s, 6H);  $^{13}$ C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  186.0, 178.9, 161.6, 135.6, 134.1, 130.7, 128.6, 100.4, 69.1, 29.0; LC-MS (ESI) m/z 232 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>13</sub>H<sub>14</sub>NO<sub>3</sub> [M<sup>+</sup>H] 232.0968, found 232.0967.

(5-(1-Hydroxycyclohexyl)isoxazol-3-yl)(phenyl)methanone (3an): <sup>13</sup> Following the general procedure as for 3aa, to the mixture of 2n (39 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1a (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3an as pale yellow oil (62.2 mg, 76%). IR (KBr, cm<sup>-1</sup>): 3517, 2934, 2859, 1742, 1698, 1448, 1286, 1218, 1174, 1016, 941, 860; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.27 (d, J = 7.5 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.51 (t, J = 7.5 Hz, 2H), 6.70 (s, 1H), 2.61 (br, 1H), 2.06-1.97 (m, 2H), 1.97-1.88 (m, 2H), 1.82-1.71 (m, 2H), 1.68-1.53 (m, 3H), 1.44-1.33 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 186.0, 178.9, 161.6, 135.7, 134.1, 130.7, 128.6, 100.8, 70.4, 36.6, 29.7, 25.1, 21.5, 13.9; LC-MS (ESI) m/z 272 [M<sup>+</sup>H].

**Phenyl**(5-(**trimethylsilyl**)**isoxazol-3-yl**)**methanone** (**3ao**): <sup>17</sup> Following the general procedure as for **3aa**, to the mixture of **2o** (39 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1a** (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ao** as a white solid (50.6 mg, 69%). M.p. 32-34 °C; IR (KBr, cm<sup>-1</sup>): 3141, 2960, 1665, 1590, 1451, 1241, 1063, 889, 845, 688; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.30 (d, J = 7.5 Hz, 2H), 7.64 (t, J = 7.5 Hz, 1H), 7.52 (t, J = 7.5 Hz, 2H), 6.97 (s, 1H), 0.40 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 186.3, 179.3, 160.2, 136.1, 133.9, 130.7, 128.5, 113.5, -1.93; LC-MS (ESI) m/z 246 [M<sup>+</sup>H].

**(4,5-Bis(trimethylsilyl)isoxazol-3-yl)(phenyl)methanone (3ap):** Following the general procedure as for **3aa**, to the mixture of **2p** (68 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (290.0 mg, 1.2 mmol) in PhCN (1.0 mL) was added **1a** (100 μL, 0.9 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 45 min and afforded the desired product **3ap** as a colorless solid (57.8 mg, 61%). M.p. 93-94 °C; IR (KBr, cm<sup>-1</sup>): 3444, 2959, 1659, 1587, 1450, 1414, 1254, 1216, 906, 841, 748, 689; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.08 (d, J = 7.5 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.50 (t, J = 7.5 Hz, 2H), 0.46 (s, 9H), 0.27 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 190.0, 183.0, 164.0, 136.6, 134.1, 130.5, 128.6, 121.6, 0.90, -0.49; LC-MS (ESI) m/z 318 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>14</sub>H<sub>12</sub>NO<sub>6</sub> [M<sup>+</sup>H] 318.1340, found 318.1337.

**Dimethyl 3-benzoylisoxazol-4,5 dicarboxylate** (**3aq**): <sup>18</sup> Following the general procedure as for **3aa**, to the mixture of **2q** (37 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1a** (50 μL, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3aq** as a white solid (65.2 mg, 75%). M.p. 92-93 °C; IR (KBr, cm<sup>-1</sup>): 2962, 1749, 1658, 1598, 1451, 1286, 1216, 1172, 1097, 902, 688; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.17 (d, J = 7.5 Hz, 2H), 7.68 (t, J = 7.5 Hz, 1H), 7.54 (t, J = 7.5 Hz, 2H), 4.03 (s, 3H), 3.90 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 183.8, 160.2, 159.9, 159.0, 155.9, 134.9, 134.8, 130.6, 128.9, 117.7, 53.7, 53.3; LC-MS (ESI) m/z 290 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>14</sub>H<sub>12</sub>NO<sub>6</sub> [M<sup>+</sup>H] 290.0665, found 290.0656.

*N*-((3-phenzoyl-4,5-dihydroisoxazol-5-yl)methyl)-*N*-((3-benzoylisoxazol-5-yl)methyl)-4-meth ylbenzenesulfonamide (3ar): Following the general procedure as for 3aa, to the mixture of 2r (74.2 mg, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (290.0 mg, 1.2 mmol) in PhCN (1.0 mL) was added 1a (100 μL, 0.9 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3ar as a white solid (70.6 mg, 43%). M.p. 128-129 °C; IR (KBr, cm<sup>-1</sup>): 3137, 1661, 1597, 1452, 1344, 1250, 1163, 1092, 896, 824, 728, 682, 545; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.22 (d, J = 7.5 Hz, 4H), 7.72 (d, J = 8.0 Hz, 2H), 7.64 (t, J = 7.5 Hz, 2H), 7.49 (t, J = 8.0 Hz, 4H), 7.30 (d, J = 8.5 Hz, 2H), 6.66 (s, 2H), 4.71 (s, 4H), 2.38 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 185.1, 167.6, 161.9, 144.7, 135.8, 135.4, 134.2, 130.6, 130.1, 128.6, 127.4, 104.9, 42.7, 21.6; LC-MS (ESI) m/z 542 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>29</sub>H<sub>24</sub>N<sub>3</sub>O<sub>6</sub>S [M<sup>+</sup>H] 542.1380, found 542.1372.

*N*,*N*-bis((3-benzoylisoxazol-5-yl)methyl)-4-methylbenzenesulfonamide (3as): Following the general procedure as for 3aa, to the mixture of 2s (74.8 mg, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (290.0 mg, 1.2 mmol) in PhCN (1.0 mL) was added 1a (100 μL, 0.9 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3as as yellow oil (81.0 mg, 51%). IR (KBr, cm<sup>-1</sup>): 2923, 2858, 1655, 1456, 1369, 1253, 1158, 1088, 888, 806, 738; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  8.21 (d, J = 7.5 Hz, 2H), 8.15 (d, J = 7.5 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.63 (t, J = 7.5 Hz, 1H), 7.58 (t, J = 7.5 Hz, 1H), 7.53-7.42 (m, 5H), 7.29 (d, J = 8.0 Hz, 2H), 6.60 (s, 1H), 5.11-5.04 (m, 1H), 4.81 (d, J = 4.0 Hz, 2H), 3.68 (dd, J = 15.0, 3.5 Hz, 1H), 3.51-3.40 (m, 2H), 3.24 (dd, J = 18.0, 8.5 Hz, 1H), 2.38 (s, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  185.7, 185.1, 168.2, 161.7, 158.0, 144.4, 135.9, 135.5, 135.4, 134.1, 133.8, 130.6, 130.3, 130.0, 128.6, 128.5, 127.3, 104.8, 82.4, 50.9, 44.1, 37.4, 21.5; LC-MS (ESI) m/z 544 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>29</sub>H<sub>26</sub>N<sub>3</sub>O<sub>6</sub>S [M<sup>+</sup>H] 544.1537, found 544.1534.

**Ethyl 3-(2-methoxybenzoyl)-isoxazole-5-carboxylate (3ba):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1b** (59.5 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ba** as yellow oil (48.1 mg, 57%). IR (KBr, cm<sup>-1</sup>): 1729, 1679, 1599, 1465, 1292, 1242, 1020, 892, 756; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 7.63 (dd, J = 7.5, 1.5 Hz, 1H), 7.57-7.50 (m, 1H), 7.31 (s, 1H), 7.05 (t, J = 7.5 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 4.45 (q, J = 7.0 Hz, 2H), 3.76 (s, 3H), 1.42 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 186.5, 163.0, 161.1, 158.9, 156.4, 134.4, 130.8, 126.7, 120.6, 112.1, 108.9, 62.6, 55.8, 14.1; LC-MS (ESI) m/z 276 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>14</sub>H<sub>14</sub>NO<sub>5</sub> [M<sup>+</sup>H] 276.0866, found 276.0864.

$$CI$$
  $O$   $CO_2Et$ 

**Ethyl 3-(2-chlorobenzoyl)-isoxazole-5-carboxylate (3ca):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1c** (61.5 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ca** as yellow oil (60.1 mg, 72%). IR (KBr, cm<sup>-1</sup>): 2986, 1741, 1687, 1586, 1438, 1276, 1235, 1184, 1014, 896, 749; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 7.65 (d, J = 7.0 Hz, 1H), 7.53-7.45 (m, 2H), 7.45-7.36 (m, 2H), 4.46 (q, J = 7.0 Hz, 2H), 1.42 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 185.8, 162.2, 161.9, 156.1, 136.0, 133.0, 132.5, 130.7, 130.6, 126.8, 108.8, 62.7, 14.1; LC-MS (ESI) m/z: 282.0 (28) [M<sup>+</sup>H (<sup>37</sup>Cl)], 280.0 (100) [M<sup>+</sup>H (<sup>35</sup>Cl)]; HRMS (ESI) m/z calcd for C<sub>13</sub>H<sub>11</sub>ClNO<sub>4</sub> [M<sup>+</sup>H] 280.0371, found 280.0371.

Me 
$$CO_2Et$$

**Ethyl 3-(3-methylbenzoyl)-isoxazole-5-carboxylate (3da):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1d** (52.3 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3da** as yellow oil (72.5 mg, 93%). IR (KBr, cm<sup>-1</sup>): 2986, 1740, 1666, 1590, 1444, 1258, 1205, 1091, 1017, 933, 751; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.09 (d, J = 7.5 Hz, 1H), 8.06 (s, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.44-7.38 (m, 2H), 4.47 (q, J = 7.0 Hz, 2H), 2.44 (s, 3H), 1.43 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 184.7, 162.2, 161.1, 156.3, 138.6, 135.3, 135.2, 131.0, 128.6, 128.1, 110.1, 62.6, 21.4, 14.1; LC-MS (ESI) m/z 260 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>14</sub>H<sub>14</sub>NO<sub>4</sub> [M<sup>+</sup>H] 260.0917, found 260.0912.

**Ethyl 3-(3-acetamidobenzoyl)-isoxazole-5-carboxylate (3ea):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1e** (71.6mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 45 mins and afforded the desired product **3ea** as a white solid (70.0 mg, 77%). M.p. 151-152 °C; IR (KBr, cm<sup>-1</sup>): 3269, 1726, 1665, 1552, 1444, 1282, 1262, 1221, 1014, 836, 758; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.24 (s, 1H), 8.04 (d, J = 8.0 Hz, 2H), 8.00 (d, J = 7.5 Hz, 1H), 7.89 (s, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.38 (s, 1H), 4.46 (q, J = 7.0 Hz, 2H), 2.21 (s, 3H), 1.43 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 183.9, 168.9, 162.1, 161.1, 156.2, 138.5, 135.6, 129.5, 126.4, 125.9, 121.6, 110.1, 62.7, 24.5, 14.1; LC-MS (ESI) m/z 303 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>15</sub>H<sub>15</sub>N<sub>2</sub>O<sub>5</sub> [M<sup>+</sup>H] 303.0975, found 303.0977.

$$\begin{array}{c} O \\ \\ N-O \end{array} \\ CO_2Et$$

**Ethyl 3-(3-fluorobenzoyl)-isoxazole-5-carboxylate** (**3fa**): Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1f** (54.1 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 1 h and afforded the desired product **3fa** as colorless oil (57.1 mg, 72%). IR (KBr, cm<sup>-1</sup>): 3474, 2985, 1740, 1672, 1584, 1445, 1256, 1205, 1013, 759; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.17-8.13 (m, 2H), 8.04-7.99 (m, 1H), 7.55-7.49 (m, 1H), 7.43 (s, 1H), 7.40-7.34 (m, 1H), 4.48 (q, J = 7.0 Hz, 2H), 1.44 (t, J = 7.0, 3H); <sup>19</sup>F NMR (CDCl<sub>3</sub>, 470 MHz): δ -111.3 (m, Ar-F); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 183.3 ( ${}^4J_{\text{C-F}} = 2.5$  Hz), 162.8 ( ${}^1J_{\text{C-F}} = 247.0$  Hz), 162.1, 161.4, 156.3, 137.1 ( ${}^3J_{\text{C-F}} = 7.0$  Hz), 130.5 ( ${}^4J_{\text{C-F}} = 8.0$  Hz), 126.8 ( ${}^4J_{\text{C-F}} = 3.0$  Hz), 121.6 ( ${}^2J_{\text{C-F}} = 21.0$  Hz), 117.4 ( ${}^2J_{\text{C-F}} = 23.0$  Hz), 110.1, 62.9, 14.2; LC-MS (ESI) m/z 264 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>13</sub>H<sub>11</sub>FNO<sub>4</sub> [M<sup>+</sup>H] 264.0667, found 264.0665.

**Ethyl 3-(4-methylbenzoyl)-isoxazole-5-carboxylate (3ga):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1g** (52.3 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ga** as a white solid (72.7 mg, 93%). M.p. 70-72 °C; IR (KBr, cm<sup>-1</sup>): 1737, 1660, 1605, 1316, 1252, 894, 763; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.21 (d, J = 8.0 Hz, 2H), 7.40 (s, 1H), 7.33 (d, J = 8.0 Hz, 2H), 4.47 (q, J = 7.0 Hz, 2H), 2.45 (s, 3H), 1.43 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 184.0, 162.3, 161.0, 156.3, 145.7, 132.7, 130.9, 129.5, 110.1, 62.6, 21.9, 14.1; LC-MS (ESI) m/z: 260 [M<sup>+</sup>H]; HRMS (ESI) m/z: calcd for C<sub>14</sub>H<sub>14</sub>NO<sub>4</sub> [M<sup>+</sup>H] 260.0917, found 260.0915.

**Ethyl 3-(4-methoxybenzoyl)-isoxazole-5-carboxylate (3ha):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1h** (59.5 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ha** as a white solid (66.2 mg, 80%). M.p. 92-94 °C; IR (KBr, cm<sup>-1</sup>): 1744, 1597, 1431, 1249, 1185, 1012, 889, 764; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.33 (d, J = 9.0 Hz, 2H), 7.40 (s, 1H), 7.00 (d, J = 9.0 Hz, 2H), 4.47 (q, J = 7.0 Hz, 2H), 3.90 (s, 3H), 1.43 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 182.6, 164.8, 162.5, 160.9, 156.4, 133.3, 128.2, 114.1, 110.2, 62.6, 55.6, 14.1; LC-MS (ESI) m/z: 276 [M<sup>+</sup>H]; HRMS (ESI) m/z: calcd for C<sub>14</sub>H<sub>14</sub>NO<sub>5</sub> [M<sup>+</sup>H] 276.0866, found 276.0863.

$$O$$
 $CO_2$ Et

**Ethyl 3-(4-fluorobenzoyl)-isoxazole-5-carboxylate (3ia):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1i** (54.1 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ia** as a white solid (68.1 mg, 86%). M.p. 61-62 °C; IR (KBr, cm<sup>-1</sup>): 1738, 1663, 1592, 1307, 1239, 894, 861, 768; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.40-8.37 (m, 2H), 7.42 (s, 1H), 7.21 (t, J = 8.5 Hz, 2H), 4.47 (q, J = 7.0 Hz, 2H), 1.44 (t, J = 7.0 Hz, 3H); <sup>19</sup>F NMR (CDCl<sub>3</sub>, 470 MHz): δ -102.3 (m, Ar-F); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 182.9, 165.8, 162.3, 161.3, 156.3, 137.7 (d,  ${}^3J_{\text{C-F}} = 10.0$  Hz), 131.7 ( ${}^4J_{\text{C-F}} = 3.0$  Hz), 116.2 (d,  ${}^2J_{\text{C-F}} = 22.0$  Hz), 110.2, 62.8, 14.3; LC-MS (ESI) m/z 264 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>13</sub>H<sub>11</sub>FNO<sub>4</sub> [M<sup>+</sup>H] 264.0667, found 264.0665.

$$O$$
 $CO_2$ Et

**Ethyl 3-(4-chlorobenzoyl)-isoxazole-5-carboxylate** (**3ja**): Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1j** (61.5 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ja** as a white solid (70.3 mg, 84%). M.p. 64-66 °C; IR (KBr, cm<sup>-1</sup>): 1741, 1656, 1581, 1239, 1177, 890, 761; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.29 (d, J = 9.0 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.42 (s, 1H), 4.48 (q, J = 7.0 Hz, 2H), 1.44 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 183.1, 162.0, 161.3, 156.2, 141.2, 133.4, 132.1, 129.1, 110.1, 62.7, 14.1; LC-MS (ESI) m/z: 282 (36) [M<sup>+</sup>H (<sup>37</sup>Cl)], 280 (100) [M<sup>+</sup>H (<sup>35</sup>Cl)]. HRMS (ESI) m/z: calcd for C<sub>13</sub>H<sub>11</sub>ClNO<sub>4</sub> [M<sup>+</sup>H] 280.0371, found 280.0369.

$$O$$
 $CO_2Et$ 

**Ethyl 3-(4-bromobenzoyl)-isoxazole-5-carboxylate (3ka):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1k** (81.5 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ka** as a white solid (88.3 mg, 91%). M.p. 74-75 °C; IR (KBr, cm<sup>-1</sup>): 2991, 1740, 1656, 1579, 1307, 1236, 1177, 1008, 888, 757; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.20 (d, J = 8.5 Hz, 2H), 7.68 (d, J = 8.5 Hz, 2H), 7.42 (s, 1H), 4.47 (q, J = 7.0 Hz, 2H), 1.43 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 183.4, 162.0, 161.3, 156.2, 133.8, 132.2, 132.1, 130.1, 110.0, 62.7, 14.1; LC-MS (ESI) m/z: 326 (88) [M<sup>+</sup>H (<sup>81</sup>Br)], 324 (90) [M<sup>+</sup>H (<sup>79</sup>Br)]. HRMS (ESI) m/z calcd for C<sub>13</sub>H<sub>11</sub>BrNO<sub>4</sub> [M<sup>+</sup>H] 323.9866, found 323.9863.

**Ethyl 3-(4-acetylbenzoyl)-isoxazole-5-carboxylate (3la):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1l** (64.9 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3la** as a white solid (66.7 mg, 77%). M.p. 73-75 °C; IR (KBr, cm<sup>-1</sup>): 1742, 1688, 1656, 1582, 1259, 1204, 904, 858; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.41 (d, J = 8.5 Hz, 2H), 8.11 (d, J = 8.5 Hz, 2H), 7.47 (s, 1H), 4.50 (q, J = 7.0 Hz, 2H), 2.69 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 197.4, 184.0, 162.0, 161.4, 156.1, 140.9, 138.3, 130.9, 128.4, 110.0, 62.8, 27.0, 14.1; LC-MS (ESI) m/z 288 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>15</sub>H<sub>14</sub>NO<sub>5</sub> [M<sup>+</sup>H] 288.0866, found 288.0864.

$$O$$
 $CO_2$ Et

**Ethyl 3-(6-methoxy-2-naphthoyl)-isoxazole-5-carboxylate** (**3ma**): Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1m** (82.0 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3ma** as a white solid (64.8 mg, 71%). M.p. 117-119 °C; IR (KBr, cm<sup>-1</sup>): 1746, 1616, 1479, 1391, 1269, 1206, 1016, 865; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.90 (s, 1H), 8.22 (dd, J = 8.5, 1.0 Hz, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.81 (d, J = 9.0 Hz, 1H), 7.45 (s, 1H), 7.21 (dd, J = 9.0, 2.0 Hz, 1H), 7.16 (s, 1H), 4.48 (q, J = 7.0 Hz, 2H), 3.95 (s, 3H), 1.45 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 183.8, 162.5, 161.0, 160.5, 156.4, 138.1, 134.0, 131.9, 130.5, 127.7, 127.4, 125.8, 119.9, 110.3, 105.8, 62.6, 55.5, 14.2; LC-MS (ESI) m/z 326 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>18</sub>H<sub>16</sub>NO<sub>5</sub> [M<sup>+</sup>H] 326.1023, found 326.1018.

$$\begin{array}{c|c}
O \\
N \\
N-O
\end{array}$$

$$\begin{array}{c}
CO_2Et \\
Ts
\end{array}$$

Ethyl 3-(1-tosyl-1H-indole-3-carbonyl)-isoxazole-5-carboxylate (3na): To the test tube were

added **1n** (132.9 mg, 0.45 mmol), **2a** (31  $\mu$ L, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.5 mL). The reaction was stirred under N<sub>2</sub> at 60 °C for 1 h. Upon completion, the reaction mixture was cooled down to room temperature, diluted with EA and washed with water and brine. The aqueous phase was then extracted with EA (3×10 mL). The combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration through a thin pad of celite, the filtrate was evaporated in vacuum to give the crude product, which was purified by column chromatography on silica gel to give the desired product **3na** as a white solid (68.2 mg, 52%). M.p. 141-142 °C; IR (KBr, cm<sup>-1</sup>): 3148, 1741, 1645, 1529, 1443, 1378, 1296, 1203, 1012, 960, 842, 757, 662, 574; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  9.04 (s, 1H), 8.43 (d, J = 7.0 Hz, 1H), 7.99 (d, J = 7.5 Hz, 1H), 7.89 (d, J = 8.5 Hz, 2H), 7.48-7.37 (m, 3H), 7.29 (d, J = 8.0 Hz, 2H), 4.49 (q, J = 7.0 Hz, 2H), 2.37 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  178.3, 162.7, 161.3, 156.3, 146.1, 136.6, 134.7, 134.4, 130.3, 127.9, 127.4, 126.2, 125.2, 122.9, 118.5, 113.3, 109.3, 62.7, 21.7, 14.2; LC-MS (ESI) m/z 439 [M<sup>+</sup>H]. HRMS (ESI) m/z calcd for C<sub>22</sub>H<sub>19</sub>N<sub>2</sub>O<sub>6</sub>S [M<sup>+</sup>H] 439.0958, found 439.0952.

$$O$$
 $CO_2Et$ 

**Ethyl 3-(thienyl)-isoxazole-5-carboxylate (3oa):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added **1o** (48.7 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product **3oa** as a white solid (53.3 mg, 71%). M.p. 78-79 °C; IR (KBr, cm<sup>-1</sup>): 1727, 1637, 1442, 1246, 1170, 743, 743; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.46 (d, J = 3.5 Hz, 1H), 7.83 (d, J = 4.5 Hz, 1H), 7.42 (s, 1H), 7.23 (t, J = 4.0 Hz, 1H), 4.47 (q, J = 7.0 Hz, 2H), 1.43 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 175.9, 162.0, 161.3, 156.2, 141.2, 137.1, 136.7, 128.9, 109.5, 62.7, 14.1; LC-MS (ESI) m/z 252 [M<sup>+</sup>H]; HRMS (ESI) m/z calcd for C<sub>11</sub>H<sub>10</sub>NO<sub>4</sub>S [M<sup>+</sup>H] 252.0325, found 252.0323.

$$O$$
 $N-O$ 
 $CO_2Et$ 

**Ethyl 3-(cyclopropanecarbonyl)isoxazole-5-carboxylate (3pa):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (290.0 mg, 1.2 mmol) in PhCN (1.0 mL) was added **1p** (59.5 mg, 0.9 mmol) in PhCN (0.5 mL) by syringe pump for 3 h. The reaction was stirred for another 2 h and afforded the desired product **3pa** as pale yellow oil (21.3 mg, 34%). IR (KBr, cm<sup>-1</sup>): 3447, 2999, 1739, 1689, 1455, 1365, 1293, 1214, 952, 766; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 7.22 (s, 1H), 4.43 (q, J = 7.0 Hz, 2H), 3.01-2.93 (m, 1H), 1.40 (t, J = 7.0 Hz, 3H), 1.33-1.27 (m, 2H), 1.18-1.12 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 193.4, 162.4, 161.6, 156.3, 107.5, 62.6, 18.7, 14.1, 13.1; LC-MS (ESI) m/z 210 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>10</sub>H<sub>12</sub>NO<sub>4</sub> [M<sup>+</sup>H] 210.0761, found 210.0758.

Ethyl 3-(1-hydroxycyclohexanecarbonyl)-isoxazole-5-carboxylate (3qa): Following the general procedure as for 3aa, to the mixture of 2a (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol) in PhCN (1.0 mL) was added 1q (55.9 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 22 h and afforded the desired product 3qa as pale yellow oil (34.2 mg, 43%). IR (KBr, cm<sup>-1</sup>): 3386, 2932, 2856, 1660, 1450, 1257, 1201, 1066, 966, 895, 730, 685, 631; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 7.32 (s, 1H), 4.45 (q, J = 7.0 Hz, 2H), 3.56 (br, 1H), 2.18-2.07 (m, 2H), 1.86-1.58 (m, 7H), 1.41 (t, J = 7.0 Hz, 3H), 1.38-1.31 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 196.7, 161.2, 159.7, 156.0, 109.7, 79.1, 62.7, 34.0, 25.1, 21.0, 14.1; LC-MS (ESI) m/z 268 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>13</sub>H<sub>18</sub>NO<sub>5</sub> [M<sup>+</sup>H] 268.1179, found 268.1179.

HO 
$$O$$
  $CO_2Et$ 

**Ethyl 3-(2-hydroxy-2-methylpropanoyl)isoxazole-5-carboxylate (3ra):** Following the general procedure as for **3aa**, to the mixture of **2a** (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (145.0 mg, 0.6 mmol), tBuCN (132 μL, 1.2 mmol) in PhCN (1.0 mL) was added **1r** (37.9 mg, 0.45 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction was stirred for another 2 h and afforded the desired product **3ra** as pale yellow oil (20.1 mg, 29%). IR (KBr, cm<sup>-1</sup>): 3514, 3137, 2986, 2938, 2294, 1743, 1702, 1586, 1460, 1369, 1295, 1194, 1018, 924, 852, 769, 616; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 7.33 (s, 1H), 4.43 (q, J = 7.0 Hz, 2H), 3.86 (br, 1H), 1.62 (s, 6H), 1.39 (t, J = 7.0 Hz, 3H);  $^{13}$ C NMR (CDCl<sub>3</sub>, 125 MHz): δ 196.6, 161.3, 159.2, 156.0, 109.5, 62.8, 30.2, 26.9, 14.1; LC-MS (ESI) m/z 228 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>10</sub>H<sub>14</sub>NO<sub>5</sub> [M<sup>+</sup>H] 228.0866, found 228.0864.

$$EtO_2C$$

O-N

N-O

 $CO_2Et$ 

(*E*)-diethyl 3,3'-terephaloylbis(isoxazole-5-carboxylate) (3sa): Following the general procedure as for 3aa, to the mixture of 2a (31 μL, 0.3 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (290.0 mg, 1.2 mmol) in PhCN (1.0 mL) was added 1s (113.6 mg, 0.9 mmol) in PhCN (0.5 mL) by syringe pump for 2 h. The reaction continued stirred for another 0.5 h and afforded the desired product 3sa as a white solid (49.9 mg, 81%). M.p. 129-131 °C; IR (KBr, cm<sup>-1</sup>): 3139, 1738, 1667, 1290, 1247, 1015, 879, 741; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.46 (s, 4H), 7.47 (s, 2H), 4.49 (q, J = 7.0 Hz, 4H), 1.45 (t, J = 7.0 Hz, 6H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 184.0, 161.9, 161.5, 156.1, 139.0, 130.8, 110.0, 62.8, 14.1; LC-MS (ESI) m/z 430 [M<sup>+</sup>NH<sub>4</sub>]; HRMS (DART) m/z calcd for C<sub>20</sub>H<sub>17</sub>N<sub>2</sub>O<sub>8</sub> [M<sup>+</sup>NH<sub>4</sub>] 430.1245, found 430.1234.

## 3. Synthetic Applications

(5-(Chloromethyl)-isoxazol-3-yl)(phenyl)methanone (3at):<sup>17</sup> Gram-scale synthesis of 3at. Following the general procedure as for 3aa, to the mixture of 2t (1 g, 13.4 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (6.47 g, 26.8 mmol) in PhCN (20.0 mL) was added 1a (2.04 g, 20 mmol) in PhCN (6.0 mL) by syringe pump for 3 h. The reaction was stirred for another 0.5 h and afforded the desired product 3at at 55 °C as a pale yellow solid (1.95 g, 66%). M.p. 46-47 °C; IR (KBr, cm<sup>-1</sup>): 2924, 2857, 1666, 1457, 1375, 1218, 891, 729; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.30 (d, J = 7.5 Hz, 2H), 7.66 (t, J = 7.5 Hz, 1H), 7.53 (t, J = 7.5 Hz, 2H), 6.86 (s, 1H), 4.70 (s, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 185.2, 168.4, 162.0, 135.5, 134.2, 130.7, 128.7, 104.7, 34.1; LC-MS (ESI) m/z 224.0 (15) [M<sup>+</sup>H (<sup>37</sup>Cl)], 222.0 (70) [M<sup>+</sup>H (<sup>35</sup>Cl)].

(5-Butylisoxazol-3-yl)(4-methoxyphenyl)methanone (3he): Following the general procedure as for 3aa, to the mixture of 2e (113 μL, 1 mmol), Cu(NO<sub>3</sub>)<sub>2</sub>·3H<sub>2</sub>O (483.3 mg, 2.0 mmol) in PhCN (3.5 mL) was added 1h (198.3 mg, 1.5 mmol) in PhCN (1.0 mL) by syringe pump for 2 h. The reaction was stirred for another 0.5 h and afforded the desired product 3he as yellow oil (109.8 mg, 42%). IR (KBr, cm<sup>-1</sup>): 2948, 1654, 1598, 1452, 1257, 1171, 1027, 893, 844, 767, 617, 404; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.32 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 6.48 (s, 1H), 3.88 (s, 3H), 2.82 (t, J = 7.5 Hz, 2H), 1.78-1.67 (m, 2H), 1.48-1.37 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 184.4, 174.5, 164.3, 162.1, 133.2, 128.8, 113.8, 101.7, 55.6, 29.5, 26.3, 22.2, 13.7; LC-MS (ESI) m/z: 260 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>15</sub>H<sub>18</sub>NO<sub>3</sub> [M<sup>+</sup>H] 260.1281, found 260.1286

**4-Methoxylphenyl 5-butylisoxazole-3-carboxylate** (**4**): To a solution of (5-butylisoxazol-3-yl)-(4-methoxyphenyl)methanone **3he** (82.0 mg, 0.32 mmol), pH = 7.5 phosphate buffer (0.6 mL) in HFIP (1.5 mL) and DCM (1.5 mL) was added 3-chloroperoxybenzoic acid (394.4 mg, 1.6 mmol) at room temperature. The reaction mixture was stirred at room temperature for 19 h. After complete consumption of the material **3he** (monitored by TLC), the reaction was quenched with saturated aqueous solution of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (16.0 mL), and washed with NaHCO<sub>3</sub> (36.0 mL). The reaction mixture was extracted with DCM (3×10 mL) and the combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by flash column chromatography on silica gel to afford compound **4** as yellow oil (72.8 mg, 88%). IR (KBr, cm<sup>-1</sup>): 3333, 2945, 1742, 1508, 1457, 1209, 1028, 823, 728; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 7.15 (d, *J* = 9.5 Hz, 2H), 6.93 (d, *J* = 9.0 Hz, 2H), 6.53 (s, 1H), 3.81 (s, 3H), 2.84 (t, *J* = 7.5 Hz, 2H), 1.78-1.69 (m, 2H), 1.47-1.38 (m, 2H), 0.96 (t, *J* = 7.5 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 176.2, 159.1, 157.7, 155.9, 143.6, 122.2, 114.6, 101.8, 55.6, 29.4, 26.4, 22.1, 13.7; LC-MS (ESI) m/z: 276 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>15</sub>H<sub>18</sub>NO<sub>4</sub> [M<sup>+</sup>H] 276.1230, found 276.1232.

**5-Butylisoxazole-3-carbohyrazide** (**5**): To a solution of 4-methoxylphenyl-5-butyl-isoxazole-3-carboxylate **4** (0.05 mmol, 13.8 mg) in EtOH (0.15 mL) was added hydrazine hydrate (6.3 mg, 0.1 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 h. After complete consumption of compound **4** (monitored by TLC), the reaction was quenched with brine (15.0 mL). The reaction mixture was extracted with EA (3×10.0 mL) and the combined organic extracts were dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and evaporation, the residue was purified by silica gel plate to afford 5-butylisoxazole-3-carbohyrazide **5** as a white solid (8.3 mg, 91%). M.p. 30-31 °C; IR (KBr, cm<sup>-1</sup>): 3289, 2955, 2867, 1677, 1589, 1541, 1455, 1246, 939, 846, 608; <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.20 (br, 1H), 6.43 (s, 1H), 4.13 (br, 2H), 2.78 (t, J = 7.5 Hz, 2H), 1.71-1.65 (m, 2H), 1.41-1.36 (m, 2H), 0.93 (t, J = 7.5 Hz, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz): δ 175.6, 160.2, 157.2, 100.5, 29.4, 26.4, 22.1, 13.6; LC-MS (ESI) m/z: 184 [M<sup>+</sup>H]; HRMS (DART) m/z calcd for C<sub>8</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub> [M<sup>+</sup>H] 184.1081, found 184.1079.

## 4. X-ray Crystallographic Analysis for Compound 3ak

Crystallographic data for compound **3ak**:  $C_{19}H_{12}N_2O_4$ , M=332.31, Triclinic, P=1 (No. 2), a=8.066 (8) Å, b=8.242 (8) Å, c=12.157 (13) Å,  $\alpha=92.727$  (13)°,  $\beta=102.604$  (12)°,  $\gamma=98.233$  (11)°, V=778.0 (14) ų, Z=2, crystal size:  $0.23\times0.19\times0.17$  mm, T=295 K,  $\rho_{calcd}=1.419$  g·cm<sup>-3</sup>,  $R_1=0.0389$  (I>4 $\sigma$ (I)),  $wR_2=0.1051$  (all data), GOF = 1.053, reflections collected/unique: 2700 / 2122 (Rint = 0.0128), Data: 2700, restraints: 0, parameters: 227. CCDC 1486863 contains the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data request/cif.

#### **5. Mechanistic Studies**

To a test tube were added  $\text{Cu}(\text{NO}_3)_2 \cdot 3\text{H}_2\text{O}$  (145.0 mg, 0.6 mmol), **1a** (50  $\mu\text{L}$ , 0.45 mmol), **2a** (31  $\mu\text{L}$ , 0.3 mmol) and PhCN (1.5 mL). The mixture was stirred under N<sub>2</sub> at 50 °C for 15 min and was quenched by H<sub>2</sub>O. The aqueous phase was then extracted with EA (3×10 mL) and the combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration through a thin pad of celite, the filtrate was evaporated in vacuum to give the crude product, which was purified by column chromatography on silica gel to give **3aa** (64.7 mg, 88%) and **6a** (3.5 mg, 7%).

To the mixture of **6a** (74.3 mg, 0.45 mmol),  $Cu(NO_3)_2 \cdot 3H_2O$  (145.0 mg, 0.6 mmol) in PhCN (1.5 mL) was added **2a** (31  $\mu$ L, 0.3 mmol). The reaction was stirred at 60 °C overnight. Then the mixture was cooled down to room temperature, and purified by column chromatography on silica gel to give **3aa** as a white solid (72.9 mg, 99%).

Ph— 
$$=$$
  $\frac{\text{Cu(NO}_3)_2 \, 3\text{H}_2\text{O} \, (2.0 \, \text{equiv.})}{\text{PhCN, 60 °C, N}_2, 1 \, \text{h}}$  Ph  $\frac{\text{O}}{\text{N-O}}$  Ph  $\frac{\text{3aa'}}{\text{73\%}}$ 

To a test tube were added  $\text{Cu}(\text{NO}_3)_2 \cdot 3\text{H}_2\text{O}$  (145.0 mg, 0.6 mmol), **1a** (50  $\mu\text{L}$ , 0.45 mmol) and PhCN (1.5 mL). The mixture was stirred under N<sub>2</sub> at 60 °C for 1 h and was quenched by H<sub>2</sub>O. The aqueous phase was then extracted with EA (3×10 mL) and the combined organic phase was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. After filtration through a thin pad of celite, the filtrate was evaporated in vacuum to give the crude product, which was purified by column chromatography on silica gel to give the product phenyl(5-phenylisoxazol-3-yl)methanone (54.6 mg, 73%).

To a test tube were added  $Cu(NO_3)_2 \cdot 3H_2O$  (145.0 mg, 0.6 mmol), **2a** (31  $\mu$ L, 0.3 mmol) and PhCN (1.5 mL). The mixture was stirred under  $N_2$  at 60 °C for 1 h and no reaction occurred.

#### Reference

- [1] S. R. Gerrard, M. M. Edrees, I. Bouamaied, K. R. Fox and T. Brown, *Org. Biomol. Chem.*, 2010, **8**, 5087.
- [2] M. Gao, Y. Li, Y. Gan and B. Xu, Angew. Chem., Int. Ed., 2015, 54, 8795.
- [3] A. Pelter and D. E. Jones, J. Chem. Soc., Perkin Trans., 2000, 1, 2289.
- [4] E. J. Jeong and I. H. Lee, Bull. Korean Chem. Soc., 2015, 36, 295.
- [5] T. Haro and C. Nevado, J. Am. Chem. Soc., 2010, **132**, 1512.
- [6] J. M. Yang, X. Y. Tang, Y. Wei and M. Shi, Adv. Synth. Catal., 2013, 355, 3545.
- [7] H. J. Song, Y. X. Liu and Q. M. Wang, Org. Lett., 2013, 15, 3274.
- [8] D. Campolo, T. Arif, C. Borie, D. Mouysset, N. Vanthuyne, J. V. Naubron, M. P.Bertrand and M. Nechab, *Angew. Chem., Int. Ed.*, 2014, **53**, 3227.
- [9] P. Wei, X. Yan, J. Li, Y. Ma, Y. Yao and F. H. Huang, *Tetrahedron*, 2012, **68**, 9179.
- [10] Y. Tsuzuki, T. K. Nguyen, D. R. Garud, B. Kuberan and M. Kokets, *Bioorg. Med. Chem. Lett.*, 2010, 20, 7269.
- [11] T. Achard, A. Lepronier, Y. Gimbert, H. Clavier, L. Giordano, A. Tenaglia and G. Buono, *Angew. Chem., Int. Ed.*, 2011, **50**, 3552.
- [12] K. I. Itoh and C. A. Horiuchi, *Tetrahedron*, 2004, **60**, 1671.
- [13] P. K. Mykhailiuk, Org. Biomol. Chem., 2015, 13, 3438.

- [14] M. I. Shevchuk, Zh. Org. Khim., 1978, 14, 2003.
- [15] J. J. Tegeler and C. J. Diamond, Hoechst-Roussel Pharmaceuticals Inc. Patent: US4562187 A1, 1985.
- [16] R. G. Chary, G. R. Reddy, Y. S. S. Ganesh, K. V. Prasad, A. Raghunadh, T. Krishna, S. Mukherjee and M. Pal, Adv. Synth. Catal., 2014, 356, 160.
- [17] K. I. Itoh, T. Aoyama, H. Satoh, Y. Fujii, H. Sakamaki, T. Takido and M. Kodomari, *Tetrahedron Lett.*, 2011, **52**, 6892.
- [18] I. Yavari, M. Piltan and L. Moradi, Tetrahedron, 2009, 65, 2067.







































































































































































